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Volume 53, Number 17S Abstracts 63Scant differences existed in discharge ambulation (WI 91.6%
vs 91.9%, p0.879), 1-year amputation (WI 12.3% vs
8.9%, p0.226), or 1-year primary patency (WI 64.4% vs
70.8%, p0.297). On multivariate analysis, predictors of
WI in IC included COPD (OR 2.24, 95% CI 1.08-4.62)
and age55 (OR 2.6, 95% CI 1.22-5.55). In CLI, predic-
tors included tibial versus popliteal target (OR 1.64, 95%CI
1.09-2.45) and age55 (OR 1.74, 95% CI 1.0-3.04).
Conclusions: In this large contemporary cohort of
patients undergoing LEB, WI rates were low and did not
have significant long-term implications. While hospital re-
source utilization secondary to prolonged LOS was in-
creased, outcomes related to function, graft patency, and
limb salvage were not affected. WI is a self-limiting compli-
cation and should not significantly impact the decision of
whether or not to perform a LEB.
Author Disclosures: J. Cronenwett: Nothing to disclose;
G. Doros: Nothing to disclose; R. Eberhardt: Nothing to
disclose; A. Farber: Nothing to disclose; N. Hamburg:
Nothing to disclose; J. Kalish: Nothing to disclose; D.
Rybin: Nothing to disclose; A. Schanzer: Nothing to
disclose; K. Tan: Nothing to disclose.
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Comparing Patency and Salvage Rates between Multi-
ple Ipsilateral Iliac Artery Stents and Isolated Iliac
Artery Stents: Beyond TASC II
Rachel C. Danczyk1, Erica L. Mitchell1, Sharon G. Kry-
ger1, Chad Burk1, Sarguni Singh1, Timothy K. Liem1,
Gregory J. Landry1, James M. Edwards2, Bryan D. Pe-
tersen3, Gregory L. Moneta1. 1Division Vascular Surgery,
OregonHealth& ScienceUniversity, Portland, OR; 2Port-
land VAMedical Center, Portland, OR; 3The Dotter Insti-
tute, Oregon Health & Science University, Portland, OR
Objectives: Endovascular stents are accepted therapy
for TASC A, B and some C lesions. Surgery is the
recommended therapy for patients with TASC D lesions
including those with both ipsilateral common iliac (CIA)
and external iliac artery (EIA) stenoses/occlusion. This
study compares anatomic patency and operative salvage
rates for combined ipsilateral CIA and EIA stenting
(TASC D) versus CIA or EIA stents alone (TASC A, B
or C).
Methods: All patients (n481) who underwent iliac
artery stenting at a single institution between 1998 and
2010 were identified. Patient comorbidities and outcomes
were retrospectively reviewed and analyses were performed
using multivariate regression and Kaplan-Meier curves.
Results: There were 325 extremities with CIA stents,
173 with EIA stents, and 137 with both CIA and EIA
stents. There was no significant difference in demographics,
comorbidities, or treatment indications between groups.
During follow-up, 160 patients died, 83 underwent endo-
vascular reintervention, and 34 required salvage operation.
Mean times to follow-up, death, reintervention, and oper- ctive salvage were 2.50.1, 5.50.3, 7.00.6, and
.80.5 years, respectively. CIA and EIA stenting in com-
ination was not a predictor of death, reintervention, or
alvage operation. Survival, reintervention-free survival,
nd salvage operation-free survival were similar between
hose who hadCIA or EIA stents alone and those with both
IA and EIA stents (all p0.05).
Conclusions: CIA stents, EIA stents, and the combi-
ation of ipsilateral CIA and EIA stents have similar out-
omes. Salvage operations for iliac artery stent failure are
ncommon and not influenced by the location or extent of
liac artery stent placement. This study suggests that a more
ggressive approach with total endovascular management
or some TASCD lesion is acceptable. TASC II recommen-
ations for endovascular therapy for aorto-iliac disease
hould be extended to consider selected patients with ipsi-
ateral CIA and EIA stenoses/occlusion.
uthor Disclosures: C. Burk: Nothing to disclose; R. C.
anczyk: Nothing to disclose; J. M. Edwards: Nothing to
isclose; S. G. Kryger: Nothing to disclose; G. J. Landry:
othing to disclose; T. K. Liem: Nothing to disclose; E. L.
itchell: Nothing to disclose; G. L. Moneta: Nothing to
isclose; B. D. Petersen: Nothing to disclose; S. Singh:
othing to disclose.
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Objectives: The use of antiplatelet agents to improve
esults of peripheral angioplasty and stenting is not well
efined. The purpose of this study was to analyze the
ontemporary use of antithrombotic therapy and the
ffect on outcome after endovascular femoropopliteal
nterventions.
Methods: All primary endovascular interventions in
he femoropopliteal arteries between 2006 and 2008
ere identified from the National Vascular Registry
Swedvasc). The cohort was cross-linked with the Na-
ional Pharmaceutical Registry providing information
bout post-procedure antithrombotic treatment. Demo-
raphics, major amputation and death were analyzed
sing logistic regression models and Kaplan-Meier sur-
ival analysis.
Results: 3281 patients underwent endovascular inter-
ention in the femoropopliteal segment (balloon angio-
lasty (PTA) 68%; stent/stentgraft 18%; subintimal angio-
lasty (SAP) 14%). Post-procedure antithrombotic therapy
as: ASA (acetylsalicylic acid) 43%, clopidogrel 5%, ASA-
lopidogrel 24%, warfarin 4%, or other 24%. Dominating
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(47%), ASA-clopidogrel (38%), and ASA-clopidogrel
(41%), respectively. Type of post-procedure antithrom-
botic therapy did not influence major amputation or death
in claudicants or patients with critical limb ischemia (CLI)
undergoing PTA or SAP. Kaplan-Meier analysis showed
better amputation-free survival and total survival with ASA-
clopidogrel treatment compared to ASA-only in patients
with CLI undergoing stenting (log rank P0.008 and
P0.047, respectively).
Conclusions: Patients with CLI undergoing stenting
in the femoropopliteal segment have insufficient adjuvant
antiplatelet treatment and dual antiplatelet therapy with
ASA and clopidogrel seem to improve amputation-free
survival. Type of post-procedure antiplatelet therapy did
not influence amputation or death in patients with CLI
undergoing PTA or SAP.
Author Disclosures: F. Granath: Nothing to disclose; J.
Malmstedt: Nothing to disclose; O. Thott: Nothing to
disclose; C. Wahlgren: Nothing to disclose.
PS132.
An Economic Analysis Regarding the Use of Axial
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Objectives: Within the context of healthcare resource
utilization, the optimal use of computed tomographic ar-
teriography (CTA) for peripheral arterial occlusive disease
is ill-defined. The purpose of this study is to use data from
a contemporary practice to examine the hypothetical im-
pact of non-selective CTA as a part of the workup algorithm
for peripheral arterial occlusive disease.
Methods: Outpatient lower extremity endovascular
cases were analyzed over a consecutive 12-month period.
Indication (claudication or critical limb ischemia), case type
(diagnostic or interventional) and charges were recorded.
Medicare charges for CTAwere used to generate hypothet-
ical charges assuming all patients underwent CTA, and that
diagnostic cases would not have undergone catheter-based
procedures. The ratio of diagnostic to interventional cases
was then examined to define the cost-effective point for
non-selective CTA use.
Results: A total of 211 cases were identified, 47% had an
indication of claudication, and 60% were male. In the claudi-
cation cohort, 32% were diagnostic and the mean current
charge (without the use of CTA) was $45,8733,002/pa-
tient. Non-selective CTA results in a mean charge
of $47,5573,545/patient (P0.72 vs. current). In the crit-
ical limb ischemia subset, 29% were diagnostic, and the mean
current charge was $52,5423,690/patient compared to a
hypothetical non-selective CTA charge of $55,7954,144/atient (P0.55 vs. current). The ratio of diagnostic-to-inter-
entional cases for non-selective CTA to be cost-effective is
.44.
Conclusions:The economic basis for non-selective use
f CTA in the anatomic workup of peripheral arterial
cclusive disease is dependent on the ratio of diagnostic to
nterventional cases. In the authors’ current practice, non-
elective CTA would not improve resource utilization,
owever other factors such as patient access, the invasive
ature of catheter-based procedures, ionizing radiation
osimetry, and iodinated contrast dose all impact this prac-
ice decision.
uthor Disclosures: W. M. Bogey: Nothing to disclose;
. A. Durham: Nothing to disclose; B. A. Ehlert: Nothing
o disclose; A. J. Ferikes: Nothing to disclose; J. T. Nelson:
othing to disclose;F. M. Parker: Nothing to disclose;C. S.
owell: Nothing to disclose; M. C. Stoner: Nothing to
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Objectives: Patients with no option critical limb isch-
mia [NOCLI] have been ascribed a 50% one-year ampu-
ation free survival (AFS) [TASC II]. Over recent years
mprovements in the medical treatments available to NO-
LI patients may affect atherosclerotic peripheral and cor-
nary artery disease. In addition advances in wound care
herapies have improved ulcer healing. We sought to deter-
ine if amputation, mortality, and AFS rates of medically
anaged NOCLI patients have changed over the last two
ecades.
Methods: We reviewed 886 control patients from 11
OCLI randomized controlled trials (RCTs)enrolled from
988 to 2010. We estimated summary proportions of
vents at 1 year by conducting a random effects meta-
nalysis of proportions with the Freeman-Tukey arcsine
ransformation method. To examine whether there is a
ignificant change in the published proportions of these
vents over time, we performed a random effects meta-
egression analysis, where we regressed the proportion of
vents in each study against the indicator variable “final year
f recruitment” in each study. This was used as a proxy
ariable for the time period during which each study was
onducted. We examined the coefficient of this indicator
ariable for direction of effect (positive or negative, show-
ng increase or decrease in proportion of events over time,
espectively).Results: See Table.
